Literature DB >> 26753544

Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study.

Jie Chen1, Shuhui Sun1, Qingran Yan1, Chunde Bao1, Qiong Fu2.   

Abstract

This study aims to identify risk factors for thrombosis in patients with systemic lupus erythematosus (SLE) and to validate the efficacy of the partial antiphospholipid (aPL) score for thrombosis prediction and diagnosis of antiphospholipid syndrome (APS). This study included 325 SLE patients, 188 of whom completed a follow-up of 31.01 months (range 23-48 months). Partial aPL score was calculated by adding up the individual scores for activated partial thromboplastin time (APTT), lupus anticoagulant, IgG/IgM anticardiolipin antibodies (aCL), and IgG/IgM anti-β2-glycoprotein I (anti-β2GPI). A simplified aPL score was developed using only APTT, IgG/IgM aCL, and IgG/IgM anti-β2GPI. Partial aPL scores were significantly higher in SLE patients with thrombosis (p < 0.0001). A history of thrombosis (p < 0.0001), a partial aPL score >10 (p < 0.0001), and immunosuppressant use (p = 0.012) were independent risk factors for thrombosis. For patients with a history of thrombosis, partial aPL score was the strongest risk factor for recurrent thrombosis (p < 0.0001, odds ratio = 30.34 (95 % CI 7.70-118.81)). For APS diagnosis, the area under the receiver-operating characteristic curve (AUC) was 0.809 (95 % CI 0.73-0.89) using the partial aPL score. Similarly, the simplified aPL score was significantly associated with thrombosis (p < 0.0001) and was acceptable for APS diagnosis (AUC 0.797, 95 % CI 0.72-0.88). An elevated partial aPL score is a strong risk factor for thrombosis in SLE patients and is a useful tool to predict recurrent thrombosis. Partial aPL score and simplified aPL score, although comprising fewer items than the original aPL score, also represent valuable quantitative indices for APS diagnosis.

Entities:  

Keywords:  Antiphospholipid antibody; Antiphospholipid syndrome; Lupus; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 26753544     DOI: 10.1007/s10067-015-3159-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.

Authors:  Emily Somers; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

Review 2.  Interpretation and recommended testing for antiphospholipid antibodies.

Authors:  Monica Galli
Journal:  Semin Thromb Hemost       Date:  2012-03-07       Impact factor: 4.180

3.  Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.

Authors:  Kotaro Otomo; Tatsuya Atsumi; Olga Amengual; Yuichiro Fujieda; Masaru Kato; Kenji Oku; Tetsuya Horita; Shinsuke Yasuda; Takao Koike
Journal:  Arthritis Rheum       Date:  2012-02

4.  Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus.

Authors:  Zhaleh Shariati Sarabi; Erika Chang; Raja Bobba; Dominique Ibanez; Dafna Gladman; Murray Urowitz; Paul R Fortin
Journal:  Arthritis Rheum       Date:  2005-08-15

5.  The global anti-phospholipid syndrome score in primary APS.

Authors:  Savino Sciascia; Giovanni Sanna; Veronica Murru; Dario Roccatello; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Rheumatology (Oxford)       Date:  2014-08-13       Impact factor: 7.580

6.  Antiphospholipid scoring: significance in diagnosis and prognosis.

Authors:  K Oku; O Amengual; T Atsumi
Journal:  Lupus       Date:  2014-10       Impact factor: 2.911

7.  Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups.

Authors:  Chi Chiu Mok; Sandy Shuk Kuen Tang; Chi Hung To; Michelle Petri
Journal:  Arthritis Rheum       Date:  2005-09

8.  Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort.

Authors:  Savino Sciascia; Maria Jose Cuadrado; Giovanni Sanna; Veronica Murru; Dario Roccatello; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-12       Impact factor: 4.794

9.  GAPSS: the Global Anti-Phospholipid Syndrome Score.

Authors:  Savino Sciascia; Giovanni Sanna; Veronica Murru; Dario Roccatello; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Rheumatology (Oxford)       Date:  2013-01-12       Impact factor: 7.580

10.  Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.

Authors:  P Mustonen; K V Lehtonen; K Javela; M Puurunen
Journal:  Lupus       Date:  2014-08-27       Impact factor: 2.911

View more
  5 in total

Review 1.  How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores.

Authors:  Kenji Oku; Olga Amengual; Shinsuke Yasuda; Tatsuya Atsumi
Journal:  Curr Rheumatol Rep       Date:  2017-08       Impact factor: 4.592

Review 2.  Prevention of thrombosis in antiphospholipid syndrome.

Authors:  Wendy Lim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Symptomatic femoral head necrosis in patients with rheumatoid arthritis: A retrospective case-control study.

Authors:  Qijiao Wei; Qing Yan; Diantian Lin; Fei Gao; He Lin; Zhihan Chen
Journal:  Immun Inflamm Dis       Date:  2022-06

4.  Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.

Authors:  Florian Posch; Johanna Gebhart; Jacob H Rand; Silvia Koder; Peter Quehenberger; Vittorio Pengo; Cihan Ay; Ingrid Pabinger
Journal:  BMC Med       Date:  2017-03-10       Impact factor: 8.775

5.  Associations between glucocorticoids, antiphospholipid antibodies and femur head necrosis in patients with SLE: a directed acyclic graph-based multicentre study.

Authors:  Shengbao Chen; Qianying Cai; Yanjun Xu; Qiong Fu; Yong Feng; Xiaoxiang Chen; Shengming Dai; Dongbao Zhao; Ce Zhan; Weidong Xu; Jiwei Wang; Yang Wang; Jinming Yu; Chunde Bao; Changqing Zhang
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-29       Impact factor: 5.346

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.